Skip to main content
Clinical Trials/NCT07436078
NCT07436078RecruitingNot Applicable

A Community-Engaged Approach to Culturally Adapting an Intervention to Increase Uptake of Genetic Testing Among African American Cancer Survivors

Barbara Ann Karmanos Cancer Institute1 site in 1 country85 target enrollmentStarted: April 18, 2026Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
85
Locations
1

Study Overview

Brief Summary

The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African Americans at risk for heredity cancers. With the help of community stakeholders and clinical genetic professionals the investigators will:

  • adapt and refine a culturally relevant online educational genetic counseling program for at-risk African Americans
  • Test the effects of the educational program
  • collaborate with community leaders and clinical genetic professionals to translate study findings, develop a road map for dissemination to the community, and identify barriers to prepare for future trials.

Participants from Detroit Research on Cancer Survivor group will be offered enrollment. Once consent is obtained, questionnaires will be completed before an online genetic counselling intervention immediately after, and at 3 months

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Health Services Research
Masking
None

Eligibility Criteria

Ages
20 Years to 79 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS)
  • Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1/1/2013
  • have received or currently receiving care at Karmanos Cancer Institute
  • meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below
  • Female breast
  • personal diagnosis at age ≤50
  • personal history of the triple-negative subtype
  • at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age <50
  • at least 1 close relative diagnosed with ovarian cancer
  • 2+ close relatives diagnosed with breast or prostate cancer
  • age <50 AND another primary breast cancer at any age
  • 2+ primary breast cancers at any age
  • OR Prostate
  • personal history of high-risk or very high-risk prostate cancer
  • personal history of regional or metastatic prostate cancer
  • personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age <60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer)
  • OR Colorectal
  • personal diagnosis at age ≤50
  • at least 1 close relative diagnosed with HNPCC at age <50
  • at least 2 close relatives diagnosed with an HNPCC cancer at any age
  • colorectal and >=1 primary endometrial, ovarian, gastric, pancreatic, or prostate

Exclusion Criteria

  • Previous genetic counseling and/or testing

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Felicity Harper

Principal Investigator

Barbara Ann Karmanos Cancer Institute

Study Sites (1)

Loading locations...

Similar Trials